Generate Biomedicines reported second quarter 2026 financial results on August 6, 2026. Revenue decreased to $6.3 million from $10.1 million in the prior year period. The company incurred a net loss of $67.3 million compared to $56.7 million previously. Research and development expenses rose to $64.3 million due to continued investment in GB-0895 Phase 3 trials, while general and administrative expenses increased to $13.6 million driven by higher stock-based compensation. Cash, cash equivalents, and marketable securities totaled $457.4 million as of June 30, 2026. The company stated its existing liquidity is sufficient to fund operations into the first half of 2028. Generate Biomedicines operates in the biotechnology industry, utilizing a generative biology platform to engineer novel therapeutics.